Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Artiva Biotherapeutics (ARTV) Non-cash Items (2023 - 2025)

Artiva Biotherapeutics (ARTV) has disclosed Non-cash Items for 3 consecutive years, with $587318.0 as the latest value for Q4 2025.

  • On a quarterly basis, Non-cash Items fell 91.75% to $587318.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $587318.0, a 91.75% decrease, with the full-year FY2025 number at $587318.0, down 91.75% from a year prior.
  • Non-cash Items was $587318.0 for Q4 2025 at Artiva Biotherapeutics, down from $7.4 million in the prior quarter.
  • In the past five years, Non-cash Items ranged from a high of $12.2 million in Q3 2024 to a low of $214000.0 in Q4 2023.
  • A 3-year average of $5.2 million and a median of $7.1 million in 2024 define the central range for Non-cash Items.
  • Peak YoY movement for Non-cash Items: soared 3226.17% in 2024, then plummeted 91.75% in 2025.
  • Artiva Biotherapeutics' Non-cash Items stood at $214000.0 in 2023, then skyrocketed by 3226.17% to $7.1 million in 2024, then tumbled by 91.75% to $587318.0 in 2025.
  • Per Business Quant, the three most recent readings for ARTV's Non-cash Items are $587318.0 (Q4 2025), $7.4 million (Q3 2025), and $7.9 million (Q2 2025).